Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Delineation of the HPV11E6 and HPV18E6 Pathways in Initiating Cellular Transformation.

Mwapagha LM, Tiffin N, Parker MI.

Front Oncol. 2017 Nov 1;7:258. doi: 10.3389/fonc.2017.00258. eCollection 2017.

2.

Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.

Ginindza TG, Sartorius B, Dlamini X, Östensson E.

PLoS One. 2017 May 22;12(5):e0177762. doi: 10.1371/journal.pone.0177762. eCollection 2017.

3.

Developments in L2-based human papillomavirus (HPV) vaccines.

Schellenbacher C, Roden RBS, Kirnbauer R.

Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Review.

PMID:
27889616
4.

Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression.

Wu X, Wang G, Chen X, Zhang J, Zhao J, Wang J, Xiao Y, Tai J, Wang S, Wang G, Wang H, Bai L, Gui J, Ni X.

Sci Rep. 2016 Nov 8;6:36378. doi: 10.1038/srep36378.

5.

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

Boiron L, Joura E, Largeron N, Prager B, Uhart M.

BMC Infect Dis. 2016 Apr 16;16:153. doi: 10.1186/s12879-016-1483-5.

6.

The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.

Mensah FA, Mehta MR, Lewis JS Jr, Lockhart AC.

Oncologist. 2016 Apr;21(4):453-60. doi: 10.1634/theoncologist.2015-0075. Epub 2016 Mar 9. Review.

7.

Total Lifetime and Cancer-related Costs for Elderly Patients Diagnosed With Anal Cancer in the United States.

Deshmukh AA, Zhao H, Franzini L, Lairson DR, Chiao EY, Das P, Swartz MD, Giordano SH, Cantor SB.

Am J Clin Oncol. 2015 Oct 29. [Epub ahead of print]

8.

The Influence of Religiosity and Spirituality on Rural Parents' Health Decision Making and Human Papillomavirus Vaccine Choices.

Thomas T, Blumling A, Delaney A.

ANS Adv Nurs Sci. 2015 Oct-Dec;38(4):E1-E12. doi: 10.1097/ANS.0000000000000094.

9.

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML.

Lancet. 2015 Nov 21;386(10008):2078-2088. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17.

10.

Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.

Khatibi M, Rasekh HR.

Iran J Pharm Res. 2015 Spring;14(2):635-49.

11.

Human papillomavirus vaccination for boys.

Quinn S, Goldman RD.

Can Fam Physician. 2015 Jan;61(1):43-6.

12.
13.

HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment.

Trimble CL.

Cancer Immunol Res. 2014 Oct;2(10):937-42. doi: 10.1158/2326-6066.CIR-14-0152. Review.

14.

Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran.

Khatibi M, Rasekh HR, Shahverdi Z, Jamshidi HR.

Iran J Pharm Res. 2014 Winter;13(Suppl):225-34.

15.

Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions.

Lazarenko LM, Nikitina OE, Nikitin EV, Demchenko OM, Kovtonyuk GV, Ganova LO, Bubnov RV, Shevchuk VO, Nastradina NM, Bila VV, Spivak MY.

EPMA J. 2014 Jan 6;5(1):1. doi: 10.1186/1878-5085-5-1.

16.

Financial implications of male circumcision scale-up for the prevention of HIV and other sexually transmitted infections in a sub-Saharan African community.

Kacker S, Frick KD, Quinn TC, Gray RH, Tobian AA.

Sex Transm Dis. 2013 Jul;40(7):559-68. doi: 10.1097/OLQ.0b013e3182945e56.

17.

Human papillomavirus vaccination: current indications and future directions.

Gattoc L, Nair N, Ault K.

Obstet Gynecol Clin North Am. 2013 Jun;40(2):177-97. doi: 10.1016/j.ogc.2013.03.007. Epub 2013 May 10.

18.

Primary prevention and vaccination for penile cancer.

Shabbir M, Barod R, Hegarty PK, Minhas S.

Ther Adv Urol. 2013 Jun;5(3):161-9. doi: 10.1177/1756287212465456.

19.

Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany.

Klussmann JP, Schädlich PK, Chen X, Rémy V.

Clinicoecon Outcomes Res. 2013 May 16;5:203-13. doi: 10.2147/CEOR.S43393. Print 2013.

20.

Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high-risk patients.

Assoumou SA, Mayer KH, Panther L, Linas BP, Kim J.

Sex Transm Dis. 2013 Apr;40(4):298-303. doi: 10.1097/OLQ.0b013e31827f4fe9.

Supplemental Content

Support Center